Fermentalg has raised US$51 million
Fermentalg has raised US$51 million. US$16 million were raised from its existing shareholders, Demeter, Emertec, and ACE, and US$35 million from news investors, equity funds BPI France, IRDI, Viveris, and Sofiprotéol.
Fermentalg engages in the R&D and production of microalgae by heterotrophic pathway for health, algofuel and aquaculture.
Oaklins’ team in France advised Fermentlag in its fundraising.
Talk to the deal team
Related deals
Cerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn moreThe Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
Learn more